Dr Agarwals Health Care Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Dr Agarwals Health Care Ltd trades at ₹508, in a confirmed uptrend and 11 weeks into that stage. That is +7.1% against its own 200-day average. It sits at 72% of a 52-week range of ₹410 to ₹546. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 6 straight weeks.

Today the stock is in a confirmed uptrend — week 11 of stage 2, confirmed. At ₹508 it trades +7.1% versus its 200-day average and sits at 72% of its 52-week range (₹410–₹546).

Against the market, two honest reads. Cumulative: over the last 1.6 years the stock moved +26% while the NIFTY 500 moved +9% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 6 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Story check

Dr Agarwals Health Care Ltd's story is not scored yet against the markers our research file set on 22 August 2026. Where it sits in its own cycle: MID_EXPANSION. Still open: The thesis fails if mature-centre demand slows while greenfield losses remain elevated and operating margins decline, because the rollout would then be consuming rather than compounding capital.

Our read, 22 August 2026. The network is growing revenue through mature-centre growth, premium procedures and expansion, but valuation, working-capital absorption and changing same-store definitions require proof that new facilities earn adequate returns.

From the numbers. Earnings have expanded while the observed PE multiple compressed. The weekly PE signal is based on limited valuation history, and the absolute multiple remains demanding despite its discount to the observed median.

From the price. Price stage 2, week 11 — above its 200-day line, relative strength rising.

From the research. The network is growing revenue through mature-centre growth, premium procedures and expansion, but valuation, working-capital absorption and changing same-store definitions require proof that new facilities earn…

🚨 Where they disagree. Earnings have expanded while the observed PE multiple compressed. The weekly PE signal is based on limited valuation history, and the absolute multiple remains demanding despite its discount to the observed median.

What is proven. The network is growing revenue through mature-centre growth, premium procedures and expansion, but valuation, working-capital absorption and changing same-store definitions require proof that new facilities earn adequate returns.

What is not proven yet. The thesis fails if mature-centre demand slows while greenfield losses remain elevated and operating margins decline, because the rollout would then be consuming rather than compounding capital.

🚨 What would change our mind. The thesis fails if mature-centre demand slows while greenfield losses remain elevated and operating margins decline, because the rollout would then be consuming rather than compounding capital.

Layer 1 read, 22 August 2026 — KEEP. Revenue rises every quarter and the multiple has halved on rising profit, yet 107x still leaves no room. Sales rose 26.1% to Rs 614 crore and profit 44.7% last quarter, with the older centres opened before FY23 generating Rs 465 crore and still growing 16.3% while carrying three-quarters of group revenue — that base is what pays for the 18 new eye-care centres opened in the quarter. The earnings multiple has fallen from 204 times to 107 times purely because profits rose, and the share price is up only 10% in a year, so the market has not yet paid for the growth. The problems are that 107 times is still a demanding price with no cushion, that new centres are currently losing about Rs 20 crore a year at group level, and that management changed the definition of a 'mature' centre this quarter…

What would change Layer 1’s mind. Operating margin falling below 27% in the next reported half-year while new-centre losses stay at or above the current Rs 20 crore — that combination would mean the rollout is consuming capital rather than compounding it, which is the timeline's own kill condition and the one thing a 107x multiple cannot survive. The specific early tell is fewer than 12 facility additions in the September quarter against a stated cadence of 12, since the whole case rests on the mature base absorbing the cost of…

Layer 2 read, 22 August 2026 — BENCH. Growth is real, but new industry capacity and loss-making sites raise the return hurdle. Jun 2026 revenue and profit growth are hard facts, and the sector turn is revenue-led. Yet the capital-cycle block shows capacity flooding into the sector as institutions leave, while the company reports greenfield startup losses. That external link is strong enough to pause a P2 stock, but not to reject an intact growth engine.

What would change Layer 2’s mind. A comparable cohort disclosure showing greenfield losses falling for two consecutive quarters would flip BENCH to ADVANCE.

The test written in advance. The thesis fails if mature-centre demand slows while greenfield losses remain elevated and operating margins decline, because the rollout would then be consuming rather than compounding capital. — the thesis as written as stated by the next result.

The test written in advance. Greenfield loss persistence — Greenfield loss persistence Reported greenfield losses remain at or above the prior cohort level while mature-centre growth slows. by the next result.

The test written in advance. Valuation execution risk — Valuation execution risk Operating profit or profit misses the base milestone while the valuation multiple remains elevated. by the next result.

What the company does. The latest quarter extended the revenue and profit trend while reported operating margin remained near the recent range. Premium cataract mix and mature-centre growth provide an operating mechanism, but greenfield staffing and facility losses remain a near-term drag. The multiple has compressed with rising earnings, yet normalized earnings do not make the valuation materially cheaper and capital efficiency remains the key test.

🚨 What the surface reading misses. The surface reading is: Profit grew faster than revenue. The research reads it further: Operating profit also increased and the current quarter is clean in the one-off ledger, so the result has an operating component rather than being solely a reported exceptional item.

🚨 What the surface reading misses. The surface reading is: The observed multiple compression can appear to make the share inexpensive. The research reads it further: The denominator is not materially depressed because normalized earnings are close to trailing earnings; the valuation change is earnings-led compression rather than a trough-margin inversion.

Lever 1 · Operating leverage — BUILDING. Mature facilities and same-store demand provide the base that can absorb expansion costs. What proves it keeps working: Mature-centre growth. It stops working if Mature-centre sales growth slows while greenfield losses remain elevated.

Lever 2 · Value-added mix — BUILDING. Premium cataract and femto adoption can increase revenue per procedure. What proves it keeps working: Premium procedure mix. It stops working if High-end procedure mix falls or realization growth fails to translate into operating profit.

Lever 3 · Management change — BUILDING. New facilities provide a multi-quarter growth runway if doctor productivity improves after opening. What proves it keeps working: Greenfield network ramp. It stops working if New-centre losses do not decline as facilities age or expansion targets are missed.

Lever 4 · Paying down debt — BUILDING. North-region growth and the proposed Chennai capacity addition can widen the network beyond its southern base. What proves it keeps working: Regional expansion and merger capacity. It stops working if Merger clearance or facility opening slips, or regional centres fail to reach expected productivity.

Sources: our stock research file (22 August 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Dr Agarwals Health Care Ltd reported ₹614 Cr of revenue in the Jun 26 quarter, +26.1% year on year. That is the 7th straight quarter of year-on-year growth. Over 6 years it has compounded at 25.6% a year. The last full year, FY26, came in at ₹2,080 Cr. The last four reported quarters add to ₹2,207 Cr.

FY26 revenue came in at ₹2,080 Cr (+21.6% on the year), capping 6 years at 25.6% compound. The latest quarter (Jun 26) printed ₹614 Cr, +26.1% year on year — the 7th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +22.9% growth against the decade's 25.6% — the current year is running slower than its own long-run rate.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Dr Agarwals Health Care Ltd's operating margin is 28.0% in the Jun 26 quarter, +2.0 percentage points against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 18.0% to 28.0%. The current quarter sits inside that band.

Why this happened. Management reports growth from mature facilities and attributes value growth to premiumization and modest price realization. The operating-leverage catapult depends on this mature base continuing to absorb the fixed cost of staffing new centres.

The latest quarter's operating margin is 28.0%, +2.0 pp against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 18.0%–28.0%.

Why the margin moved: operating margin went +1.5 pp year on year while gross margin went +0.1 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Dr Agarwals Health Care Ltd earned ₹55.0 Cr of net profit in the Jun 26 quarter, +44.7% year on year. It is the 7th consecutive quarter of growth. Full-year FY26 profit was ₹168 Cr. That is 9.0% of the quarter's revenue. The same quarter a year earlier earned ₹38.0 Cr.

Jun 26 profit was ₹55.0 Cr, +44.7% year on year — the 7th consecutive quarter of growth. On the full year, FY26 printed ₹168 Cr (+52.7%).

Why profit moved: revenue contributed +26.1% and the margin +2.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +47.4% vs revenue +22.9%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 328% of Dr Agarwals Health Care Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹519 Cr of operating cash against ₹168 Cr of profit. After ₹713 Cr of capital spending, ₹−194 Cr was left as free cash.

FY26: operating cash of ₹519 Cr against reported profit of ₹168 Cr, leaving free cash of ₹−194 Cr after ₹713 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 328% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 328%: the cash cycle stretched 171 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.

Router verdict: the bigger cash user is investment — capital spending ran 3.5× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Dr Agarwals Health Care Ltd's cash conversion cycle runs −76 days in FY26, up from −247 days in FY21. Capital spending ran ₹2,398 Cr over the last 3 years. At FY26 sales of ₹2,080 Cr each day of that cycle holds about ₹5.7 Cr, so roughly ₹−433 Cr sits inside the business at any moment.

FY26: debtors at 28 days, inventory at 178 days — roughly 5.9 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −76 days, looser than FY21's −247.

The full loop: cash goes out to suppliers and production on day 0; stock waits 178 days to sell; customers pay about 28 days after that; and suppliers themselves are paid at 283 days — netting out to the −76-day cycle.

In money terms: at FY26 sales of ₹2,080 Cr, each day of the cycle holds about ₹5.7 Cr — so the −76-day loop keeps roughly ₹−433 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹2,398 Cr over the last 3 fiscal years against ₹677 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹234 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Dr Agarwals Health Care Ltd earns a ROCE of 11% in FY26. That is up from a trough of −1% in FY21. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 8.1% net margin on 0.53× asset turns.

FY26 ROCE is 11%, recovered from a FY21 trough of −1% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 8.1% net margin × 0.53× asset turns × 1.95× balance-sheet leverage ≈ 8.4% on equity. Margin does its share; leverage is a meaningful part of the equation.

The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 31% on reported income across 10 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Dr Agarwals Health Care Ltd carries ₹1,066 Cr of borrowings against ₹2,026 Cr of equity in FY26, a debt-to-equity of 0.53. Operating profit covers the interest bill 6×. Over 5 years borrowings went from ₹185 Cr to ₹1,066 Cr. Capital spending ran ₹2,398 Cr across the last 3 of those years.

Why this happened. The latest call reports North-region growth and dates the remaining merger clearance. Contribution remains a forecast until the facility opens and reports operating results.

FY26: borrowings of ₹1,066 Cr against equity of ₹2,026 Cr — a debt-to-equity of 0.53. Operating profit covers the interest bill 6×. Over 5 years borrowings went from ₹185 Cr to ₹1,066 Cr while capital spending ran ₹2,398 Cr in just the last 3 — part of the build-out is riding on borrowed money.

The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 31% on reported income across 10 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Foreign institutions cut 2.6 points of Dr Agarwals Health Care Ltd over 5 quarters, the biggest move on the register. That takes foreign institutions to 58.0% of the company. Domestic institutions moved +2.5 points over the same window, to 7.7%. The register is read on the four disclosed classes only; nothing is inferred between filings.

Why this happened. The latest call documents rapid additions and upfront staffing. Management expects doctor productivity and facility economics to improve as cohorts mature, making reported greenfield losses the key counter-metric.

The register over the last two years — Foreign institutions: −2.6 points over 5 quarters to 58.0%; Domestic institutions: +2.5 points over 5 quarters to 7.7%; Promoters: −0.1 points over 5 quarters to 32.3%.

Why the register moved: rotation — foreign institutions −2.6 points against domestic institutions +2.5 points over 5 quarters, with promoters holding steady — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Dr Agarwals Health Care Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Dr Agarwals Health Care Ltd trades at 109.0× P/E, near the bottom of its own range — cheaper only 8% of the time. Its long-run median P/E is 137.2×, measured across 1.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 109.0× is near the bottom of its own range — cheaper only 8% of the time, against a long-run median of 137.2× measured over 1.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +59.1% against a +17.3% price move — earnings outran the price, pushing the multiple DOWN its own range.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 31% on reported income across 10 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Dr Agarwals Health Care Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 7 quarters across 1 curve, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

4-Factor Sector Score

55.6/100 — rank 2 of 7 in Hospitals/Medical Services · 69% evidence confidence

Dr Agarwals Health Care Ltd scores 55.6 out of 100 against the 7 companies it is compared with in Hospitals/Medical Services, ranking 2. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 29.5 + 9.6 + 8.5 + 8 = 55.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Said versus delivered

What Dr Agarwals Health Care Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

Mature-Facility SSSG Definition Changed · 4 August 2026. In the Feb 2026 and May 2026 calls, management defined its mature cohort as facilities operational or opened prior to FY22 and reported approximately 14% same-store sales growth. In the Aug 2026 call, management changed the cutoff to facilities operational prior to FY23 while reporting 16.3% growth, without explaining the definition change or providing a comparable restated figure. Adding the FY22 vintage to the mature cohort could make the latest SSSG appear stronger and weakens comparability for valuation models.

Refractive Surgery Growth Reversal · 4 February 2026. Management previously guided in August 2025 that refractive surgeries would bounce back in Q2 and Q3 to mirror overall strong surgical volume growth, citing specific seasonality and planned aggression. However, in the February 2026 call, they admitted refractive business was slow in Q3 (the previously touted peak quarter) and for the full year, blaming industry sluggishness rather than delivering the promised recovery. Earlier call (Aug 2025): “The quarters where we also go aggressive... are the quarter 2 and quarter 3. Those are the 2 quarters where we get the maximum impact... overall, yes, it should mirror whatever the overall surgical growth is.” Later call (Feb 2026): “Refractive has been slow for us this quarter and largely for this year. It is more to do with the overall industry being slightly slow.”

🚨 Subsidiary Hospital Project Delay · 4 February 2026. In the August 2025 call, management stated the flagship subsidiary hospital project was back on track following flood delays and targeted operations to begin by Q4 FY26. In the latest call (which took place during Q4 FY26), this timeline was pushed back significantly by another two quarters to Q2 FY27 without detailed justification for the new slippage. Earlier call (Aug 2025): “But right now, it”. Later call (Feb 2026): “We expect to complete everything and receive all licenses and approvals by Q2 FY27.”

Massive Cut in FY26 CAPEX Guidance · 31 October 2025. In the May 2025 and August 2025 calls, management consistently guided for a total FY26 capex of INR 310 crores. However, in the October 2025 call, management confirmed a significantly reduced guidance of INR 110 crores, a 65% cut, without providing any justification for the dramatic change in capital allocation plans. Later call (Oct 2025): “Yes, 110 crores. That is 70 crores for the facility itself.”

Every quote above is taken word for word from the company’s own earnings calls.

Frequently asked questions